BioNTech to Acquire Clinical-Stage Biopharma Biotheus

TL;DR

BioNTech is buying Biotheus to boost its cancer drug pipeline.

AI Summary

On November 13, 2024, BioNTech SE announced the signing of a definitive agreement to acquire Biotheus, a clinical-stage biopharmaceutical company. This acquisition aims to strengthen BioNTech's oncology pipeline.

Why It Matters

This acquisition could significantly expand BioNTech's oncology drug development capabilities and potentially lead to new treatments for cancer patients.

Risk Assessment

Risk Level: medium — Acquisitions carry inherent risks related to integration, regulatory approval, and the actual success of the acquired company's pipeline assets.

Key Players & Entities

• BioNTech SE (company) — Acquiring company
• Biotheus (company) — Acquired company
• November 13, 2024 (date) — Date of agreement signing

FAQ

From the Filing

0001776985-24-000094.txt : 20241113 0001776985-24-000094.hdr.sgml : 20241113 20241113064943 ACCESSION NUMBER: 0001776985-24-000094 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 4 CONFORMED PERIOD OF REPORT: 20241113 FILED AS OF DATE: 20241113 DATE AS OF CHANGE: 20241113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BioNTech SE CENTRAL INDEX KEY: 0001776985 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: 2M FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39081 FILM NUMBER: 241451095 BUSINESS ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 BUSINESS PHONE: 0049613190840 MAIL ADDRESS: STREET 1: AN DER GOLDGRUBE 12 CITY: MAINZ STATE: 2M ZIP: 55131 6-K 1 form6-kbiotheusacquisition.htm 6-K Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF NOVEMBER 2024 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant’s name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐ Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐ DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K On November 13, 2024, BioNTech SE and Biotheus announced the signing of a definitive agreement for the acquisition of Biotheus, a clinical-stage biotechnology company dedicated to the discovery and development of novel antibodies to address unmet medical needs of patients with oncological or inflammatory diseases. The press release is attached as Exhibit 99.1. SIGNATURE Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioNTech SE By: /s/ Jens Holstein By: /s/ Dr. Sierk Poetting Name: Jens Holstein Name: Dr. Sierk Poetting Title: Chief Financial Officer Title: Chief Operating Officer Date: November 13, 2024 EXHIBIT INDEX Exhibit Description of Exhibit 99.1 BioNTech to Acquire Biotheus to Boost Oncology Strategy EX-99.1 2 a99_1biontechtoacquirebiot.htm EX-99.1 Document Exhibit 99.1          BioNTech to Acquire Biotheus to Boost Oncology Strategy • Acquisition to support the global execution of BioNTech’s oncology strategy and provide full global rights to BNT327/PM8002, an investigational PD-L1 x VEGF-A bispecific antibody, with potential to replace current checkpoint inhibitor standard of care treatments for solid tumors • With the acquisition of Biotheus, BioNTech aims to further strengthen its capabilities to develop, manufacture and commercialize next-generation bispecific antibodies and novel treatment combinations • BioNTech and Biotheus plan to initiate multiple registrational trials with BNT327/PM8002 in late 2024 and 2025&#59; further clinical trials evaluating BNT327/PM8002 as combination therapies are planned to start in 2024 and 2025 • BioNTech to pay $800 million to acquire 100 percent of the issued share capital and up to $150 million in potential milestone payments • Additional details will be shared at BioNTech’s Innovation Series R&D Day event on 14 November 2024 MAINZ, Germany, November 13, 2024 (GLOBE NEWSWIRE)  -- BioNTech SE&#160